ATE361915T1 - Die hiv-replikation inhibierende pyrimidine und triazine - Google Patents

Die hiv-replikation inhibierende pyrimidine und triazine

Info

Publication number
ATE361915T1
ATE361915T1 AT04737252T AT04737252T ATE361915T1 AT E361915 T1 ATE361915 T1 AT E361915T1 AT 04737252 T AT04737252 T AT 04737252T AT 04737252 T AT04737252 T AT 04737252T AT E361915 T1 ATE361915 T1 AT E361915T1
Authority
AT
Austria
Prior art keywords
triazines
pyrimidines
hiv replication
inhibiting hiv
inhibiting
Prior art date
Application number
AT04737252T
Other languages
English (en)
Inventor
Jerome Guillemont
Elisabeth Pasquier
Jan Heeres
Kurt Hertogs
Eva Bettens
Paulus Lewi
Jonge Marc De
Lucien Koymans
Frederik Daeyaert
Hendrik Vinkers
Paul Janssen
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE361915T1 publication Critical patent/ATE361915T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04737252T 2003-02-20 2004-02-20 Die hiv-replikation inhibierende pyrimidine und triazine ATE361915T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100411 2003-02-20
US47501203P 2003-06-02 2003-06-02

Publications (1)

Publication Number Publication Date
ATE361915T1 true ATE361915T1 (de) 2007-06-15

Family

ID=32910137

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04737251T ATE506353T1 (de) 2003-02-20 2004-02-20 Die hiv-replikation inhibierende indan- substituierte pyrimidine
AT04737252T ATE361915T1 (de) 2003-02-20 2004-02-20 Die hiv-replikation inhibierende pyrimidine und triazine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04737251T ATE506353T1 (de) 2003-02-20 2004-02-20 Die hiv-replikation inhibierende indan- substituierte pyrimidine

Country Status (27)

Country Link
US (2) US7585870B2 (de)
EP (2) EP1597238B1 (de)
JP (2) JP4586013B2 (de)
KR (2) KR20050094896A (de)
CN (2) CN100572364C (de)
AP (1) AP2005003373A0 (de)
AR (2) AR044499A1 (de)
AT (2) ATE506353T1 (de)
AU (2) AU2004213187B2 (de)
BR (2) BRPI0407741B8 (de)
CA (2) CA2516699C (de)
CL (2) CL2004000303A1 (de)
CY (1) CY1106788T1 (de)
DE (2) DE602004006383T2 (de)
DK (1) DK1597238T3 (de)
EA (2) EA010423B1 (de)
ES (1) ES2287734T3 (de)
HR (2) HRP20050820A2 (de)
IL (2) IL169596A (de)
MX (2) MXPA05008867A (de)
MY (1) MY138308A (de)
NO (2) NO20054312L (de)
NZ (2) NZ542428A (de)
PL (2) PL226954B1 (de)
PT (1) PT1597238E (de)
TW (2) TW200500346A (de)
WO (2) WO2004074262A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
EP1814878B1 (de) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2114902B1 (de) * 2006-12-29 2014-09-17 Janssen R&D Ireland Hiv-inhibierende 5,6-substituierte pyrimidine
JP5185283B2 (ja) * 2006-12-29 2013-04-17 テイボテク・フアーマシユーチカルズ Hiv阻害6−置換ピリミジン
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
KR101258331B1 (ko) 2008-09-11 2013-04-26 화이자 인코포레이티드 헤테로아릴 아미드 유도체 및 글루코키나제 활성화제로서의 그의 용도
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
MY151246A (en) 2009-03-11 2014-04-30 Pfizer Benzofuranyl derivatives
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012135641A2 (en) 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JP6740452B2 (ja) * 2016-07-26 2020-08-12 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
EP3966207B1 (de) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidin-amid-autophagie-hemmer und verfahren zu ihrer verwendung
MX2021013662A (es) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
IL325201A (en) 2019-06-17 2026-02-01 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of using them

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
CN1198655C (zh) 1995-11-23 2005-04-27 詹森药业有限公司 通过熔体挤出法制备的环糊精固体混合物
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EP0945447A1 (de) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
CZ299380B6 (cs) * 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
HRP20080359B1 (hr) * 1998-11-10 2016-01-01 Janssen Pharmaceutica N.V. PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CA2384188C (en) * 1999-09-24 2008-06-17 Janssen Pharmaceutica N.V. Antiviral compositions
WO2001025220A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
AU2002216650A1 (en) * 2000-10-31 2002-05-15 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
KR100875362B1 (ko) * 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AU2003244098A1 (en) * 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
ES2445208T3 (es) * 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.

Also Published As

Publication number Publication date
EP1603887A1 (de) 2005-12-14
JP2006518356A (ja) 2006-08-10
CN1751031A (zh) 2006-03-22
BRPI0407741B8 (pt) 2021-05-25
CN100572364C (zh) 2009-12-23
WO2004074262A1 (en) 2004-09-02
NO20054312D0 (no) 2005-09-19
NO20054311D0 (no) 2005-09-19
CN1751030A (zh) 2006-03-22
PL378136A1 (pl) 2006-03-06
TW200500346A (en) 2005-01-01
AP2005003373A0 (en) 2005-09-30
EP1597238B1 (de) 2007-05-09
WO2004074261A1 (en) 2004-09-02
BRPI0407741B1 (pt) 2018-05-29
ATE506353T1 (de) 2011-05-15
DE602004006383D1 (de) 2007-06-21
BRPI0407732A (pt) 2006-02-14
MXPA05008867A (es) 2005-10-05
EA200501327A1 (ru) 2006-02-24
DK1597238T3 (da) 2007-09-10
CA2516699A1 (en) 2004-09-02
HRP20050820A2 (en) 2006-11-30
AU2004213186B2 (en) 2009-10-01
AU2004213186A1 (en) 2004-09-02
IL169647A0 (en) 2007-07-04
PT1597238E (pt) 2007-08-08
NO20054311L (no) 2005-10-27
IL169647A (en) 2013-05-30
NZ541601A (en) 2007-09-28
PL378064A1 (pl) 2006-02-20
NO20054312L (no) 2005-11-16
MY138308A (en) 2009-05-29
CL2004000303A1 (es) 2005-04-08
US20060194804A1 (en) 2006-08-31
JP2006518357A (ja) 2006-08-10
ES2287734T3 (es) 2007-12-16
AR044499A1 (es) 2005-09-14
DE602004006383T2 (de) 2008-01-10
CA2516589C (en) 2012-04-17
EA010423B1 (ru) 2008-08-29
AR044500A1 (es) 2005-09-14
EP1597238A1 (de) 2005-11-23
EP1603887B1 (de) 2011-04-20
PL227295B1 (pl) 2017-11-30
US7585870B2 (en) 2009-09-08
NZ542428A (en) 2007-11-30
JP4586014B2 (ja) 2010-11-24
IL169596A (en) 2017-02-28
US20060142571A1 (en) 2006-06-29
IL169596A0 (en) 2007-07-04
CN1751031B (zh) 2010-07-21
CL2004000306A1 (es) 2005-04-08
HRP20050821A2 (en) 2006-11-30
CY1106788T1 (el) 2012-05-23
BRPI0407741A (pt) 2006-02-14
KR20050099994A (ko) 2005-10-17
CA2516589A1 (en) 2004-09-02
US7442705B2 (en) 2008-10-28
JP4586013B2 (ja) 2010-11-24
EA200501326A1 (ru) 2006-02-24
MXPA05008866A (es) 2005-10-05
TW200510339A (en) 2005-03-16
KR20050094896A (ko) 2005-09-28
AU2004213187B2 (en) 2009-11-05
AU2004213187A1 (en) 2004-09-02
CA2516699C (en) 2011-07-12
PL226954B1 (pl) 2017-10-31
DE602004032321D1 (de) 2011-06-01
EA011256B1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
ATE361915T1 (de) Die hiv-replikation inhibierende pyrimidine und triazine
ATE376420T1 (de) Mikrobizide pyrimidine oder triazine zur vorbeugung der sexuellen übertragung von hiv
ATE448210T1 (de) Pyrimidin, triazin und pyrazinderivate als glutamatrezeptoren
EG24684A (en) HIV replication inhibiting pyrimidines
NO20024308L (no) Arylsubstituerte pyridiner, pyrimidiner og triaziner og deres anvendelse
ATE341546T1 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
DE50213202D1 (de) Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
IL180760A0 (en) Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
PL375390A1 (en) 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
IL180963A0 (en) Hiv inhibiting bicyclic pyrimidine derivatives
ATE386727T1 (de) Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf)
NO20040122L (no) Fremgangsmåte for fremstilling av aminopyrimidinforbindelser samt pyrimidinforbindelser
PL1644343T3 (pl) Pochodne 5-podstawionego chinazolinonu
SE0301654D0 (sv) Novel compounds
ZA200506622B (en) HIV replication inhibiting pyrimidines and triazines
GB0323137D0 (en) 2,4,6- Trisubstituted pyrimidines and their different uses
TWI315199B (en) Hiv replication inhibiting pyrimidines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1597238

Country of ref document: EP

REN Ceased due to non-payment of the annual fee